CIMPRESS plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CIMPRESS plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.40B | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $3.29B | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $3.08B | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $2.89B | Aug 9, 2024 |
| FY2023 | Jun 30, 2021 | $2.58B | Aug 4, 2023 |
| FY2020 | Jun 30, 2020 | $429.11M | Aug 11, 2020 |
| FY2020 | Mar 31, 2020 | $597.96M | Aug 11, 2020 |
| FY2020 | Dec 31, 2019 | $820.33M | Aug 11, 2020 |
| FY2020 | Sep 30, 2019 | $633.96M | Aug 11, 2020 |
| FY2020 | Jun 30, 2019 | $674.71M | Aug 11, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Jun 30, 2015 | $380.47M | Aug 14, 2015 |
| FY2015 | Mar 31, 2015 | $339.90M | Aug 14, 2015 |
| FY2015 | Dec 31, 2014 | $439.91M | Aug 14, 2015 |
| FY2015 | Sep 30, 2014 | $333.93M | Aug 14, 2015 |
| FY2015 | Jun 30, 2014 | $338.16M | Aug 14, 2015 |
| FY2015 | Mar 31, 2014 | $286.19M | Aug 14, 2015 |
| FY2015 | Dec 31, 2013 | $370.81M | Aug 14, 2015 |
| FY2015 | Sep 30, 2013 | $275.09M | Aug 14, 2015 |
| FY2014 | Jun 30, 2013 | $280.07M | Aug 15, 2014 |
| FY2014 | Mar 31, 2013 | $287.68M | Aug 15, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $14.95M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $173.68M | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | ($185.98M) | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | ($54.33M) | Aug 9, 2024 |
| FY2023 | Jun 30, 2021 | ($85.23M) | Aug 4, 2023 |
| FY2020 | Jun 30, 2020 | ($42.01M) | Aug 11, 2020 |
| FY2020 | Mar 31, 2020 | ($84.88M) | Aug 11, 2020 |
| FY2020 | Dec 31, 2019 | $190.22M | Aug 11, 2020 |
| FY2020 | Sep 30, 2019 | $20.03M | Aug 11, 2020 |
| FY2020 | Jun 30, 2019 | $34.15M | Aug 11, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $226.27M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $247.35M | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $57.31M | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $47.30M | Aug 9, 2024 |
| FY2023 | Jun 30, 2021 | $123.51M | Aug 4, 2023 |
| FY2022 | Jun 30, 2020 | $55.97M | Aug 5, 2022 |
| FY2021 | Jun 30, 2019 | $163.61M | Aug 6, 2021 |
| FY2020 | Jun 30, 2018 | $157.80M | Aug 11, 2020 |
| FY2019 | Jun 30, 2017 | ($45.70M) | Aug 9, 2019 |
| FY2015 | Jun 30, 2015 | $96.32M | Aug 14, 2015 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $65.00M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $62.66M | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $58.82M | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $57.00M | Aug 9, 2024 |
| FY2023 | Jun 30, 2021 | $49.25M | Aug 4, 2023 |
| FY2022 | Jun 30, 2020 | $49.20M | Aug 5, 2022 |
| FY2021 | Jun 30, 2019 | $40.98M | Aug 6, 2021 |
| FY2020 | Jun 30, 2018 | $41.45M | Aug 11, 2020 |
| FY2015 | Jun 30, 2015 | $30.85M | Aug 14, 2015 |
| FY2015 | Jun 30, 2014 | $26.42M | Aug 14, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $298.07M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $350.72M | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $130.29M | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $219.54M | Aug 9, 2024 |
| FY2023 | Jun 30, 2021 | $265.22M | Aug 4, 2023 |
| FY2022 | Jun 30, 2020 | $338.44M | Aug 5, 2022 |
| FY2021 | Jun 30, 2019 | $331.10M | Aug 6, 2021 |
| FY2020 | Jun 30, 2018 | $192.33M | Aug 11, 2020 |
| FY2019 | Jun 30, 2017 | $156.74M | Aug 9, 2019 |
| FY2015 | Jun 30, 2015 | $228.88M | Aug 14, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $89.02M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $54.93M | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $53.77M | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $54.04M | Aug 9, 2024 |
| FY2023 | Jun 30, 2021 | $38.52M | Aug 4, 2023 |
| FY2022 | Jun 30, 2020 | $50.47M | Aug 5, 2022 |
| FY2021 | Jun 30, 2019 | $70.56M | Aug 6, 2021 |
| FY2020 | Jun 30, 2018 | $60.93M | Aug 11, 2020 |
| FY2019 | Jun 30, 2017 | $74.16M | Aug 9, 2019 |
| FY2015 | Jun 30, 2015 | $75.81M | Aug 14, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.97B | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $1.89B | Aug 8, 2025 |
| FY2024 | Jun 30, 2023 | $1.85B | Aug 9, 2024 |
| FY2023 | Jun 30, 2022 | $2.17B | Aug 4, 2023 |
| FY2022 | Jun 30, 2021 | $2.18B | Aug 5, 2022 |
| FY2021 | Jun 30, 2020 | $1.82B | Aug 6, 2021 |
| FY2020 | Jun 30, 2019 | $1.87B | Aug 11, 2020 |
| FY2019 | Jun 30, 2018 | $1.65B | Aug 9, 2019 |
| FY2015 | Jun 30, 2015 | $1.31B | Aug 14, 2015 |
| FY2015 | Jun 30, 2014 | $988.99M | Aug 14, 2015 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $2.53B | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $2.42B | Aug 8, 2025 |
| FY2024 | Jun 30, 2023 | $2.47B | Aug 9, 2024 |
| FY2023 | Jun 30, 2022 | $2.53B | Aug 4, 2023 |
| FY2022 | Jun 30, 2021 | $2.56B | Aug 5, 2022 |
| FY2021 | Jun 30, 2020 | $2.15B | Aug 6, 2021 |
| FY2020 | Jun 30, 2019 | $1.67B | Aug 11, 2020 |
| FY2019 | Jun 30, 2018 | $1.47B | Aug 9, 2019 |
| FY2015 | Jun 30, 2015 | $1.00B | Aug 14, 2015 |
| FY2015 | Jun 30, 2014 | $745.37M | Aug 14, 2015 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($583.49M) | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | ($550.15M) | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | ($623.15M) | Aug 8, 2025 |
| FY2025 | Jun 30, 2022 | ($494.92M) | Aug 8, 2025 |
| FY2024 | Jun 30, 2021 | ($449.37M) | Aug 9, 2024 |
| FY2023 | Jun 30, 2020 | ($407.48M) | Aug 4, 2023 |
| FY2022 | Jun 30, 2019 | ($131.81M) | Aug 5, 2022 |
| FY2021 | Jun 30, 2018 | $93.66M | Aug 6, 2021 |
| FY2020 | Jun 30, 2017 | $75.00M | Aug 11, 2020 |
| FY2019 | Jun 30, 2016 | $165.73M | Aug 9, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $826.16M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $787.14M | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $781.54M | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $766.60M | Aug 9, 2024 |
| FY2023 | Jun 30, 2021 | $726.98M | Aug 4, 2023 |
| FY2022 | Jun 30, 2020 | $621.90M | Aug 5, 2022 |
| FY2021 | Jun 30, 2019 | $718.88M | Aug 6, 2021 |
| FY2019 | Jun 30, 2018 | $520.84M | Aug 9, 2019 |
| FY2019 | Jun 30, 2017 | $514.96M | Aug 9, 2019 |
| FY2015 | Jun 30, 2015 | $400.63M | Aug 14, 2015 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $225.12M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $272.88M | Aug 8, 2025 |
| FY2024 | Jun 30, 2023 | $235.40M | Aug 9, 2024 |
| FY2023 | Jun 30, 2022 | $414.14M | Aug 4, 2023 |
| FY2022 | Jun 30, 2021 | $530.16M | Aug 5, 2022 |
| FY2021 | Jun 30, 2020 | $618.44M | Aug 6, 2021 |
| FY2020 | Jul 1, 2019 | $540.41M | Aug 11, 2020 |
| FY2020 | Jun 30, 2019 | $537.42M | Aug 11, 2020 |
| FY2019 | Jul 1, 2018 | $449.51M | Aug 9, 2019 |
| FY2019 | Jun 30, 2018 | $452.76M | Aug 9, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $233.98M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $203.78M | Aug 8, 2025 |
| FY2024 | Jun 30, 2023 | $130.31M | Aug 9, 2024 |
| FY2023 | Jun 30, 2022 | $277.05M | Aug 4, 2023 |
| FY2022 | Jun 30, 2021 | $183.02M | Aug 5, 2022 |
| FY2021 | Jun 30, 2020 | $45.02M | Aug 6, 2021 |
| FY2021 | Jun 30, 2019 | $35.28M | Aug 6, 2021 |
| FY2021 | Jun 30, 2018 | $44.23M | Aug 6, 2021 |
| FY2020 | Jun 30, 2017 | $25.70M | Aug 11, 2020 |
| FY2019 | Jun 30, 2016 | $77.43M | Aug 9, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jun 30, 2019 | $1.04B | Aug 9, 2019 |
| FY2013 | Jun 30, 2013 | $238.75M | Aug 15, 2013 |
| FY2011 | Jun 30, 2011 | $0 | Aug 17, 2011 |
| FY2011 | Jun 30, 2010 | $5.22M | Aug 17, 2011 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | 6 | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | (7) | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | (2) | Aug 9, 2024 |
| FY2023 | Jun 30, 2021 | (3) | Aug 4, 2023 |
| FY2020 | Jun 30, 2020 | (1) | Aug 11, 2020 |
| FY2020 | Mar 31, 2020 | (3) | Aug 11, 2020 |
| FY2020 | Dec 31, 2019 | 7 | Aug 11, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Aug 11, 2020 |
| FY2020 | Jun 30, 2019 | 1 | Aug 11, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | 6 | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | (7) | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | (2) | Aug 9, 2024 |
| FY2022 | Jun 30, 2021 | (3) | Aug 5, 2022 |
| FY2020 | Jun 30, 2020 | (1) | Aug 11, 2020 |
| FY2020 | Mar 31, 2020 | (3) | Aug 11, 2020 |
| FY2020 | Dec 31, 2019 | 6 | Aug 11, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Aug 11, 2020 |
| FY2020 | Jun 30, 2019 | 1 | Aug 11, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 24.48M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | 25.08M | Aug 8, 2025 |
| FY2024 | Jun 30, 2023 | 26.34M | Aug 9, 2024 |
| FY2023 | Jun 30, 2022 | 26.11M | Aug 4, 2023 |
| FY2022 | Jun 30, 2021 | 26.04M | Aug 5, 2022 |
| FY2021 | Jun 30, 2020 | 25.89M | Aug 6, 2021 |
| FY2020 | Jun 30, 2019 | 30.45M | Aug 11, 2020 |
| FY2019 | Jun 30, 2018 | 30.88M | Aug 9, 2019 |
| FY2015 | Jun 30, 2015 | 33.20M | Aug 14, 2015 |
| FY2015 | Jun 30, 2014 | 32.33M | Aug 14, 2015 |